Welcome to our dedicated page for Anika Therapeutics news (Ticker: ANIK), a resource for investors and traders seeking the latest updates and insights on Anika Therapeutics stock.
Anika Therapeutics Inc (ANIK) specializes in innovative orthopedic solutions using hyaluronic acid technology for joint preservation and regenerative therapies. This news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements and strategic initiatives.
Access timely press releases covering regulatory milestones, financial results, and product developments. Our curated collection includes updates on osteoarthritis pain management innovations, surgical partnership expansions, and research breakthroughs in tissue repair technologies.
Key content categories feature earnings announcements, FDA clearances, OEM collaborations, and clinical trial outcomes. All information is sourced directly from the company to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to ANIK's latest medical technology updates and market-moving developments. Check regularly for authoritative information supporting informed analysis of the company's position in the orthopedic sector.
Anika Therapeutics reported a 4% revenue increase in Q2 2022, totaling $39.7 million compared to $38.1 million in the same quarter of 2021. Key revenue segments included OA Pain Management at $25.7 million (6% up) and Joint Preservation and Restoration at $12.1 million (2% up). However, the company posted a net loss of $2.8 million, down from a net income of $6.5 million a year prior. Gross margin stood at 63%, with adjusted gross margin at 67%. The FDA granted 510(k) clearance for the X-Twist Fixation System, with a limited release planned for the second half of 2022, signaling potential growth avenues ahead.
Anika Therapeutics (NASDAQ: ANIK) has received the ACE Award from the AOSSM for its Tactoset Injectable Bone Substitute. This calcium phosphate-based product, enhanced with hyaluronic acid, improves the management of inferior bone quality, crucial for successful surgical interventions such as rotator cuff repairs. It doubles the pull-out strength of suture anchors in osteoporotic bone models, highlighting its efficacy. Launched in 2019 and FDA-cleared in 2021, Tactoset offers a simpler solution for surgeons, addressing microfractures without the need for larger hardware.
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced plans to release its Q2 2022 financial results after the market close on August 3, 2022. The company will also hold an investor conference call at 5:00 p.m. ET on the same day to discuss financial results and business highlights. Investors can access the call by dialing 1-888-220-8474 or via a live audio webcast available on Anika's website. The company specializes in joint preservation and minimally invasive orthopedic solutions, focusing on osteoarthritis management and sports medicine.
On June 10, 2022, Anika Therapeutics (NASDAQ: ANIK) announced participation in the Sidoti Small Cap Virtual Investor Conference on June 15, 2022. The management will host a virtual presentation with a Q&A session starting at 11:30 am ET. Investors can access the webcast through the Investor Relations section of Anika's website and an archived version will also be available later. Anika focuses on joint preservation and offers innovative solutions in early intervention orthopedics, including products for osteoarthritis pain management.
Anika Therapeutics announced FDA clearance for its X-Twist Knotless Fixation System, enhancing its offerings for rotator cuff repairs and other orthopedic procedures. The system's design allows for versatile knotless fixation, suitable for various soft tissue applications. Anika plans to begin commercialization in the second half of 2022, targeting the growing market of nearly 670,000 rotator cuff procedures performed in 2021. This clearance positions Anika favorably within the ambulatory surgery center market, aiming for accelerated growth in its Sports Medicine segment.
Anika Therapeutics (NASDAQ: ANIK) announced on May 2, 2022, the granting of stock options and restricted stock units (RSUs) to five newly hired non-executive employees. A total of 13,091 options were granted at an exercise price of $21.61, and 16,113 options at $23.77, which is 110% of the closing price on the grant date. The RSUs covered 20,818 shares. These grants are part of the 2021 Inducement Plan and serve as incentives for employment. Vesting for both options and RSUs occurs over three years, contingent on continuous service to the company.
On May 9, 2022, Anika Therapeutics (NASDAQ: ANIK) announced its participation in the UBS Global Healthcare Conference 2022. The event will take place in-person on May 25, 2022, at the Lotte New York Palace, New York, NY. Anika's management will host a live presentation featuring a fireside chat, starting at 11:30 AM ET. Additionally, they will engage in one-on-one investor meetings on the same day. The presentation will be accessible via a webcast on Anika’s Investor Relations page, with an archive available post-event.
Anika Therapeutics reported a 7% increase in Q1 2022 revenue, reaching $36.7 million, primarily driven by improved order timing in OA Pain Management.
OA Pain Management revenue surged 18% to $22.7 million, while Joint Preservation and Restoration dipped 1% and Non-Orthopedic revenue fell 34%.
The company faced a net loss of $2.9 million, starkly contrasting with a net income of $2.8 million in Q1 2021. Adjusted EBITDA was $2.6 million, down from $4.8 million.
Anika anticipates revenue growth in FY 2022, mainly from Joint Preservation and Restoration, but expects Non-Orthopedic revenue to decline by approximately 20%.
Anika Therapeutics, a joint preservation company, announced the grant of stock options and restricted stock units to three new non-executive employees on April 1, 2022. A total of 10,662 stock options and 5,024 RSUs were awarded under the 2021 Inducement Plan, approved by the compensation committee. The options have an exercise price of $25.50, aligning with the stock's closing price on the grant date. Vesting occurs in equal installments over three years, contingent on continuous service. These grants do not require shareholder approval.
Anika Therapeutics (NASDAQ: ANIK) will release its Q1 2022 financial results on May 5, 2022, after market close. The company will host an investor conference call at 5:00 p.m. ET to discuss the financial outcomes and notable business developments. Interested participants can join the call by dialing the provided numbers and using conference ID 2795291. A live audio webcast and accompanying presentation will be accessible on Anika's website, with recordings available post-call.
FAQ
What is the current stock price of Anika Therapeutics (ANIK)?
What is the market cap of Anika Therapeutics (ANIK)?
